RhoGDI2抑制膀胱癌转移的分子机制

膀胱癌在中国男性泌尿生殖系恶性肿瘤发病率居第1位，其发病率呈逐年上升趋势。RhoGDI2（rho GDP dissociation inhibitor 2）是近年来发现的新型膀胱癌转移抑制因子，其分子机制可能通过调控下游erbB1/EGFR酪氨酸受体、钙结合蛋白S100A4、p53和MTSS1等基因而抑制膀胱癌进展。RhoGDI2基因表达缺失的膀胱癌患者预后不良。RhoGDI2基因表达可以作为判断膀胱癌患者是否容易发生转移的基因信号，有望在临床上成为抑制膀胱癌的治疗分子。本文针对RhoGDI2的发现、在膀胱癌病理标本的表达情况和对膀胱癌转移的影响、在肿瘤转移中的作用、抑制膀胱癌转移的分子机制作一综述。

Molecular Mechanism of RhoGDI2 Inhibiting Metastasis of Bladder Cancer

Bladder cancer is the first common urogenital malignant tumor among the Chinese men, and the incidence is trending to rapidly ascend. Rho GDP dissociation inhibitor 2(RhoGDI2) is found to be a new metastasis suppressor factor of bladder cancer in recent years. Previous studies have confirmed that RhoGDI2 protein can inhibit bladder cancer metastases, and its molecular mechanism maybe regulate the downstream gene of erbB1/EGFR tyrosine kinase receptor, calcium binding protein S100A4, p53 and MTSS1 which stop tumor progression. RhoGDI2 gene deletion also is a poor prognostic factor in patients with bladder cancer. In conclusion, expression of RhoGDI2 gene can be as a signal for diagnosis of patients with bladder cancer prone to metastasis. RhoGDI2 is expected to be a therapeutic molecules inhibiting bladder cancer. In this paper,we give an overview of RhoGDI2 function in bladder carcinoma. These include the RhoGDI2 discovery, RhoGDI2 expression in pathological specimens, and the molecular mechanism that RhoGDI2 inhibits the metastasis.